Deferred Tax Assets, Net of Valuation Allowance of Dianthus Therapeutics, Inc. /DE/ from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Dianthus Therapeutics, Inc. /DE/ Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 31 Dec 2025 was $480,000, a 111% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)

Dianthus Therapeutics, Inc. /DE/ Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $480,000 +$253,000 +111% 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q4 2024 $227,000 -$13,082,000 -98% 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q4 2023 $13,309,000 +$13,113,000 +6690% 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q4 2022 $196,000 +$190,000 +3167% 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q4 2021 $6,000 -$1,373,000 -100% 31 Dec 2021 8-K 21 Dec 2023
Q4 2020 $1,379,000 -$194,000 -12% 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q4 2019 $1,573,000 +$1,212,000 +336% 31 Dec 2019 10-K 03 Mar 2021 2020 FY
Q4 2018 $361,000 +$315,000 +685% 31 Dec 2018 10-K 03 Mar 2020 2019 FY
Q4 2017 $46,000 31 Dec 2017 10-K 19 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.